Sykehuset Østfold HF, Moss
- Address
- Peer Gynts vei 78, 1535 Moss, Norway
Sykehuset Østfold HF - Rheumatology and Vasculitis Research
Sykehuset Østfold HF in Moss is actively engaged in advanced clinical research focusing on inflammatory vascular diseases. The center demonstrates particular expertise in evaluating novel therapeutic approaches for complex autoimmune conditions, contributing to the development of innovative treatment strategies that aim to reduce long-term corticosteroid dependency.
- Giant cell arteritis and large vessel vasculitis
- Biologic therapies and glucocorticoid-sparing regimens
- Phase III efficacy and safety trials in rheumatologic conditions
The research center's participation in international Phase III studies reflects its commitment to evidence-based medicine in rheumatology. By investigating secukinumab and other targeted biologics in conditions like giant cell arteritis, the facility plays a crucial role in advancing treatment options that potentially offer improved outcomes while minimizing the adverse effects associated with prolonged corticosteroid therapy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sykehuset Østfold HF, Moss
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Secukinumab and Glucocorticoid Taper in Giant Cell Arteritis Patients | Novartis Pharma AG | Phase III | Not Recruiting | Oct 2021 | Feb 2026 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Prednisone | 1 | Unknown | 2021-10-06 | 2021-10-06 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.